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increase in fetuin-A, a major inhibitor of (extra-skeletal)
calcium-phosphate deposition, may help to offset the risk of
vitamin D therapy-induced increase in calcium-phosphate
product. However, the observed increase as presented in their
ﬁgure was much delayed, and so it is unlikely to be a direct
effect of the analog treatment. Moreover, the effects of
vitamin D on vascular wall and cardiovascular risks are
extremely complex and involve mostly beneﬁcial effects but
also possible deleterious effects at very high vitamin D levels.2
Ectopic vascular calciﬁcation is a complex phenomenon whereby
mesenchymal cells are redirected to become osteoblast-like
cells that can produce matrix and deposit minerals that then
become calciﬁed vascular lesions.3–5 The vitamin D hormone
and its analogs can indeed induce this (trans)differentiation
in vitro, but in vivo results with either the parent vitamin D
compound6 or vitamin D analogs,3 together with the
beneﬁcial effects of vitamin D analog treatment in chronic
renal failure (CRF) patients7 on overall survival and
cardiovascular events, clearly demonstrate that the vitamin
D effect is much more complex. A poor vitamin D status is
indeed associated with increased prevalence of cardiovascular
risk and events in the general population8 as well as in CRF
patients, so that correction of poor vitamin D status may
improve cardiovascular risks although this requires conﬁrma-
tion by the appropriate randomized controlled trials (RCTs).
The process of vascular mineralization is enhanced by high
phosphate, oxidative stress, vitamin D, and parathyroid
hormone (PTH) (fragments), and bone morphogenic
proteins, but is also inhibited by inhibitors of mineraliza-
tion such as fetuin-A, osteopontin, and matrix gamma-
carboxyglutamate (Gla) protein. Moreover, ﬁbroblast growth
factor (FGF23) and its receptor and co-receptor Klotho are
also very potent regulators of vascular function and even
survival or longevity, but their precise role in the vascular
function or dysfunction needs further clariﬁcation.9,10 There-
fore, the observation of Manenti et al. are just the very brief
start of a series of much needed studies to document the
process of accelerated vascular dysfunction in CRF patients so
as to deﬁne the real culprit and potential natural protectors.
This will allow then to better deﬁne the relative importance of
control of serum calcium, phosphate, and calciotropic
hormones, including FGF23 and Klotho, in the prevention
of cardiovascular and mortality risks. It seems logical that
only a combination of in vitro and in vivo studies in
appropriate animal models and prospective RCTs in
human patients will be able to provide us with the necessary
answers.
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interest in our study. Despite no direct evidence showing
the transcriptional regulation of fetuin-A by vitamin D,
paricalcitol might increase fetuin-A production, given that
vitamin D itself has an anti-inflammatory action and that
fetuin-A is a negative acute-phase protein. The lack of
significant correlation between changes in fetuin-A and those
in high-sensitivity C-reactive protein cannot rule out this
possibility, because the number of the patients is so small.
The effect of vitamin D on vascular calciﬁcation appears to be
dependent on the dosage of vitamin D.2 High-dose vitamin D
increases calcium-phosphate product and promotes vascular
calciﬁcation, whereas vitamin D at therapeutic doses can reduce
calciﬁcation by suppressing aortic osteoblastic gene expression.2
Thus, it may not be appropriate to directly compare the result
from rats treated with toxic doses of vitamin D and the one
from humans treated with therapeutic doses.
It is very important to take fetuin-A fractions into consi-
deration when discussing the roles of fetuin-A. Our quoted
paper3 insisted that measuring fetuin-mineral complex (FMC)
rather than fetuin-A is important for evaluating calciﬁcation
stress. Recently, we found that similar FMC could be separated
in the serum of patients with chronic kidney disease (CKD).4
Our results in CKD patients indicated that serum fetuin-A
levels in humans determined by enzyme-linked immunosorbent
assay were the sum of the fetuin-A level bound to calcium and
the free fetuin-A level, and that the former reﬂects ongoing
calciﬁcation stress. From this perspective, further studies seem
to be required to elucidate which type of fetuin-A is increased
by paricalcitol.
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The ‘ball-in-cup’ lesion is
not specific for human
immunodeficiency virus-related
glomerulonephritis
To the Editor: We have read with interest the papers on
human immunodeﬁciency virus (HIV)-related nephropathy
from South Africa.1,2 We have a comment concerning the
HIV-related glomerulonephritis, where several biopsies
showed ‘ball-in-cup’ lesions, characterized by subepithelial
deposits with a peculiar basement membrane reaction.
These lesions had the appearance of a hybrid between
post-infectious and membranous glomerulonephritis.
Gerntholtz et al.2 consider this lesion typical for HIV
infection, and speculate that the deposits might contain viral
particles.
We have limited experience with HIV-related kidney
disease in our countries. However, we have encountered
similar lesions in HIV-negative patient groups, among them
in lupus nephritis and in post-infectious glomerulonephritis
(before the HIV era). A woman transplanted for lupus
nephritis had a biopsy taken 3 years after transplantation,
showing recurrence of membranous lupus nephritis
(Figure 1a). A man with lecithin cholesterol acyltransferase
deﬁciency had a biopsy with large lipid-rich deposits in all
compartments of the glomerulus, some of which as
subepithelial ‘ball-in-cup’ lesions (Figure 1b).
As the pathogenesis of this lesion is unknown, one might
speculate that damage or stimulus of the podocytes incites
these cells to produce increased amounts of basement
membrane material. The pattern may evolve not only in
immune complex diseases, such as lupus nephrits, but also in
cases where non-immune lipid laden deposits are involved, as
in lecithin cholesterol acyltransferase disease. In our opinion,
the ‘ball-in-cup’ lesion may be typical for HIV-related
immune complex glomerulonephritis, but not speciﬁc for
this disease group.
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Figure 1 |Renal biopsies with ‘ball-in-cup’ lesions.
(a) Subepithelial deposit in graft recurrent membranous
glomerulonephritis in systemic lupus. Electron microscopy,
 7000. (b) Subepithelial deposit in lecithin cholesterol
acyltransferase disease. Electron microscopy,  9000.
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